专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011125139A1 CLUAP1 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： CLUAP1包括其中的肽和疫苗
公开(公告)号：WO2011125139A1
公开(公告)日：2011-10-13
申请号：PCT/JP2010/006313
申请日：2010-10-26
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K39/00 , A61P35/00 , C07K14/705 , C07K16/00 , C12N5/10 , C12N15/00
CPC分类号： C07K14/4748 , A61K39/0011 , G01N2333/47 , G01N2333/775
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the CLUAP1 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredient peptides derived from CLUAP1 or polynucleotides encoding the peptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from CLUAP1, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的CLUAP1基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供了含有作为活性成分的衍生自CLUAP1的肽或编码肽作为活性成分的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自CLUAP1的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

2. 发明申请

WO2011002772A1 IMIDAZOPYRIDINE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME 审中-公开
标题翻译：咪唑吡啶衍生物和含有它们的PBK抑制剂
公开(公告)号：WO2011002772A1
公开(公告)日：2011-01-06
申请号：PCT/US2010/040394
申请日：2010-06-29
申请人： ONCOTHERAPY SCIENCE, INC. , MATSUO, Yo , HISADA, Shoji , OHSAWA, Ryuji , WALKER, Joel, R. , LI, Yingfu , AHMED, Feryan , NAKAMURA, Yusuke
发明人： MATSUO, Yo , HISADA, Shoji , OHSAWA, Ryuji , WALKER, Joel, R. , LI, Yingfu , AHMED, Feryan , NAKAMURA, Yusuke
IPC分类号： A61K31/535
CPC分类号： A61K31/535 , C07D471/04
摘要： Imidazopyridine Derivatives, which are useful for PBK inhibitors, are provided. For example, the present invention provides compounds having following general formula described herein.
摘要翻译：提供了可用于PBK抑制剂的咪唑并吡啶衍生物。例如，本发明提供具有本文所述的以下通式的化合物。

3. 发明申请

WO2010131452A1 TTK PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TTK肽和疫苗，包括它们
公开(公告)号：WO2010131452A1
公开(公告)日：2010-11-18
申请号：PCT/JP2010/003166
申请日：2010-05-10
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K38/00 , A61P35/00 , C07K16/18 , C12N15/09
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/572 , C07K14/4748
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的TTK基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有作为活性成分的衍生自TTK的肽或编码肽的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自TTK的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

4. 发明申请

WO2010064430A1 WDRPUH EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： WDRPUH EPITOPE PEPTIDES和含有其的疫苗
公开(公告)号：WO2010064430A1
公开(公告)日：2010-06-10
申请号：PCT/JP2009/006573
申请日：2009-12-03
申请人： ONCOTHERAPY SCIENCE, INC. , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C07K7/06 , A61K39/00 , A61P35/00 , C12N5/0783 , C12N5/0786 , C12N15/09
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1764 , A61K39/0011 , C07K14/47 , C07K14/4748 , C12N5/0638 , C12N5/0639
摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
摘要翻译：本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。本发明的肽也可以用作疫苗。

5. 发明申请

WO2009153992A1 CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： CDCA1 EPITOPE PEPTIDES和含有它的疫苗
公开(公告)号：WO2009153992A1
公开(公告)日：2009-12-23
申请号：PCT/JP2009/002771
申请日：2009-06-18
申请人： ONCOTHERAPY SCIENCE, INC. , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko
发明人： TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko
IPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61P35/00 , A61P43/00 , C07K16/44 , C12N5/00 , C12N15/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/53 , A61K2039/572 , A61K2039/575 , C07K14/47 , C12N5/0638
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，本发明描述了衍生自引起CTL的CDCA1的表位肽。本发明还提供了特异性识别用肽脉冲的HLA-A24阳性靶细胞的已建立的CTL。还提供了呈递任何肽的抗原呈递细胞和外来体以及诱导抗原呈递细胞的方法。本发明还提供含有CDCA1多肽或其编码多核苷酸以及作为活性成分的外来体和抗原呈递细胞的药剂。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用 CDCA1多肽，编码多肽的多核苷酸，呈递多肽的外来体或抗原呈递细胞，或本发明的药剂。要靶向的癌症包括但不限于乳腺癌，膀胱癌，食管癌，小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）。

6. 发明申请

WO2011122022A1 ECT2 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： ECT2肽和疫苗，包括它们
公开(公告)号：WO2011122022A1
公开(公告)日：2011-10-06
申请号：PCT/JP2011/001909
申请日：2011-03-30
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C12N15/09
CPC分类号： C07K7/06 , A61K39/0011 , A61K2039/572
摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore- mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.
摘要翻译：衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性的原始序列。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。

7. 发明申请

WO2011111392A1 HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： HJURP肽和疫苗，包括它们
公开(公告)号：WO2011111392A1
公开(公告)日：2011-09-15
申请号：PCT/JP2011/001407
申请日：2011-03-10
申请人： ONCOTHERAPY SCIENCE, INC. , NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： NAKAMURA, Yusuke , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C12N15/09 , A61K35/00 , A61K38/00 , C07K7/06 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/00 , C12N5/10
CPC分类号： C07K14/4748 , A61K35/12 , A61K38/00 , A61K39/00 , C07K7/06 , C07K16/18
摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
摘要翻译：衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗的上下文，更具体地，本文描述了癌症疫苗。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸序列被取代，缺失，添加或插入，只要这些修饰形式保留原始序列的必需细胞毒性T细胞诱导性。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物特别用于治疗癌症和肿瘤，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

8. 发明申请

WO2011080796A1 ANTI-CDH3 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗CDH3抗体及其用途
公开(公告)号：WO2011080796A1
公开(公告)日：2011-07-07
申请号：PCT/JP2009/007333
申请日：2009-12-28
申请人： ONCOTHERAPY SCIENCE, INC. , SHIBA, Yasuhiro , YOSHIOKA, Hiroki , YAMAMOTO, Shinji , KUDO, Aiko , OHSAWA, Ryuji , NG, Pohsing , NAKAMURA, Yusuke , ENDO, Keigo
发明人： SHIBA, Yasuhiro , YOSHIOKA, Hiroki , YAMAMOTO, Shinji , KUDO, Aiko , OHSAWA, Ryuji , NG, Pohsing , NAKAMURA, Yusuke , ENDO, Keigo
IPC分类号： C07K16/30 , A61K39/395 , A61P35/00 , C12N15/09 , G01N33/53 , G01N33/534 , G01N33/574 , G01N33/577 , C12P21/08
CPC分类号： C07K16/28 , A61K51/1027 , A61K2039/505 , C07K16/065 , C07K2317/41 , C07K2317/56 , G01N33/574 , G01N2333/705
摘要： The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.
摘要翻译：本发明涉及可用放射性同位素标记的抗CDH3抗体。此外，本发明提供包含抗CDH3抗体作为活性成分的方法和药物组合物。由于CDH3在胰腺，肺癌，结肠癌，前列腺癌，乳腺癌，胃癌或肝癌细胞中强烈表达，本发明可用于胰腺，肺癌，结肠癌，前列腺癌，乳腺癌，胃癌或肝癌的治疗。

9. 发明申请

WO2010073551A1 C1ORF59 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： C1ORF59肽和疫苗，包括它们
公开(公告)号：WO2010073551A1
公开(公告)日：2010-07-01
申请号：PCT/JP2009/006944
申请日：2009-12-17
申请人： ONCOTHERAPY SCIENCE, INC. , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
发明人： TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko , WATANABE, Tomohisa
IPC分类号： C12N15/00 , A61K39/00 , A61P35/00 , C07K7/06 , C07K14/705
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , C07K14/4748 , C12N2710/16222 , G01N33/57484 , G01N2333/47
摘要： The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 43 or immunologically active fragments thereof, which bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents and compositions of this invention may be used for treating cancer or tumor.
摘要翻译：本发明提供具有与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导能力的具有SEQ ID NO：43的氨基酸序列或其免疫活性片段的分离的肽。本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。还提供了编码任何这些上述肽的核酸以及包含任何上述肽或核酸的药剂和组合物。本发明的肽，核酸，药物和组合物可用于治疗癌症或肿瘤。

10. 发明申请

WO2010021111A1 INHBB EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： INHBB EPITOPE肽和含有它的疫苗
公开(公告)号：WO2010021111A1
公开(公告)日：2010-02-25
申请号：PCT/JP2009/003894
申请日：2009-08-14
申请人： ONCOTHERAPY SCIENCE, INC. , TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko
发明人： TSUNODA, Takuya , OHSAWA, Ryuji , YOSHIMURA, Sachiko
IPC分类号： C12N15/09 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/06
CPC分类号： C07K4/12 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/572 , C07K7/06 , C07K14/47 , G01N2500/00
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from INHBB that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical compositions containing the INHBB polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the INHBB polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，本发明描述了衍生自引发CTL的INHBB的表位肽。本发明还提供了特异性识别用肽脉冲的HLA-A02阳性靶细胞的已建立的CTL。还提供了呈递任何肽的抗原呈递细胞和外来体以及诱导抗原呈递细胞的方法。本发明进一步提供含有INHBB多肽或其编码多核苷酸以及作为活性成分的外来体和抗原呈递细胞的药物组合物。此外，本发明提供了用于治疗和/或预防癌症和/或预防其术后复发的方法，以及诱导CTL的方法，使用INHBB多肽诱导抗肿瘤免疫的方法，编码多肽，外来体或呈递多肽的抗原呈递细胞，或本发明的药剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式